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Introduction
There is growing evidence that pharmakokinetic para-
meters of commonly used antibiotics may not be opti-
mal in the critically ill patients. Significant changes of
pharmacokinetic parameters, including volume of distri-
bution and clearance, could be expected. Recently, dose
increases of antibiotics in the ICU have been advocated
to maximise their antibacterial activity, especially when
severe infections with high bacterial load and/or multi-
drug resistance are suspected.
Objectives
The objective of this study was to describe the phar-
macokinetics of tigecycline in critically ill patients
receiving continuous venovenous haemodialysis
(CVVHD) and to evaluate the frequency of pharmaco-
kinetic/pharmacodynamic target attainment with high
dosing strategy (200 mg loading dose and 100 mg/
12h).
Methods
This was a prospective observational study in critically
ill patients receiving CVVHD and administered tigecy-
cline in high doses. Serial tigecycline concentrations in
plasma were measured 2, 4, 8 and 12 hours during
antibiotic therapy. Tigecycline pharmacokinetic para-
meters were calculated using a non-compartmental
approach.
Results
Over the study period, 16 patients treated with CVVHD
received tigecycline at a high dose. There were no
patients requiring tigecycline discontinuation or dose
reduction because of adverse events.
Conclusions
Tigecycline was well tolerated at a higher than standard
dose in a cohort of critically ill patients with severe
infections requiring CVVHD.The pharmacokinetic-phar-
macodynamic profile of dosing regimen tested in this
study might be helpful in selecting the appropriate dose
of tigecycline for patients receiving CVVHD.
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